tiprankstipranks
pc:syrem

Syremis Therapeutics

Syremis Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines to improve the treatment of mental health disorders. The company’s neuropsychiatric pipeline focuses on mechanisms such as muscarinic M1/M4 agonism and next-generation NMDA antagonism, with lead program ST-905 in Phase 1 for schizophrenia and other psychiatric conditions.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$165M
Total Amount Raised$165M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$165M
Latest Funding Amount$165M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Dec 18, 2025
Series A
$165.00M

Investors

Investor Name
Funding Round
Series A
Series A
Series A

Related News and Analysis